Yuhan Corporation Partners with Cyrus Therapeutics for Targeted Cancer Therapy Research

"Expectations for the Discovery of the Second Rekraja"

Yuhan Corporation announced on the 6th that it has signed a Memorandum of Understanding (MOU) with Cyrus Therapeutics, a biotech company specializing in new drug development, to develop small molecule targeted anticancer therapies.

Yuhan Corporation has signed a Memorandum of Understanding (MOU) with Cyrus Therapeutics Inc. to develop innovative small molecule targeted anticancer therapies. Kim Byung-moon, CEO of Cyrus Therapeutics (left), and Cho Wook-je, CEO of Yuhan Corporation, are posing for a commemorative photo after signing the agreement.
[Photo by Yuhan Corporation]

Through this MOU, the two companies plan to collaborate by utilizing Cyrus Therapeutics' small molecule targeted therapy development and small molecule degrader development technologies in areas such as ▲basic research for anticancer drug development ▲joint development of anticancer drug candidates ▲technology transfer and commercialization.

Jo Wook-je, CEO of Yuhan Corporation, said, "Through cooperation with Cyrus, which has strong capabilities in developing small molecule anticancer therapies, we expect to rapidly discover a second Lekraza with global competitiveness in anticancer drug development. The anticancer field is an area where Yuhan has accumulated extensive know-how through the development experience of Lekraza, and we anticipate that fast development will be possible through collaboration between the two companies."

Kim Byung-moon, CEO of Cyrus, stated, "We expect that the combination of Cyrus's anticancer drug discovery capabilities and Yuhan Corporation's translational clinical research capabilities will create great synergy, leading to the development of world-class new drugs and establishing a model case where both companies win."

Cyrus Therapeutics is a biotech company specializing in new drug development that possesses technologies ranging from small molecule therapeutic development to the development of a new modality, targeted protein degradation (TPD). In 2023, it presented a total of three new drug candidates related to lung cancer at the American Association for Cancer Research (AACR) Annual Meeting.

This content was produced with the assistance of AI translation services.